Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 1 · 25%

Active TB · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).

1 finding from 1 review

Adherence · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).

1 finding from 1 review

Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).

1 finding from 1 review

Hepatotoxicity · HIV‐negative people at risk of TB infection1

Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).

1 finding from 1 review